Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$100.66 USD

100.66
1,338,879

-0.01 (-0.01%)

Updated Aug 12, 2024 04:00 PM ET

After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (200 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ethan Feller headshot

Momentum Monday: Inflation Data in Focus this Week

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays

Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP

by Zacks Equity Research

Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Zacks.com featured highlights include Cardinal Health, Toll Brothers, Iron Mountain, NetApp and Ralph Lauren

by Zacks Equity Research

Cardinal Health, Toll Brothers, Iron Mountain, NetApp and Ralph Lauren are part of the Zacks Screen of the Week article.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.

Medtronic's (MDT) MiniMed 780G System Study Data Favorable

by Zacks Equity Research

Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend

by Zacks Equity Research

Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.

Labcorp (LH) Introduces Weight Loss Management Portfolio

by Zacks Equity Research

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

by Zacks Equity Research

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

by Zacks Equity Research

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

by Zacks Equity Research

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone

by Zacks Equity Research

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

Maharathi Basu headshot

5 Stocks Favored by Brokers Amid Current Uncertainty

by Maharathi Basu

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.

Sweta Killa headshot

5 Dividend Stocks With High Growth Prospects

by Sweta Killa

Cardinal Health (CAH), Toll Brothers (TOL), Iron Mountain (IRM), NetApp (NTAP) and Ralph Lauren (RL) have strong dividend growth prospects.

Davita (DVA) Shares Gain This Week: Will the Rally Continue?

by Zacks Equity Research

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

by Zacks Equity Research

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Best Growth Stocks to Buy for March 8th

by Zacks Equity Research

POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.

Abbott (ABT) to Reduce Childhood Malnutrition With New Pact

by Zacks Equity Research

Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

by Zacks Equity Research

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.